Clinical Trial Update: Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating deferiprone for acute kidney injury in CKD patients undergoing catheterization with contrast has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Deferiprone (deferiprone)

Snippet

Sponsor: CorMedix | Conditions: Acute Kidney Injury | Phase 3 | Status: WITHDRAWN